Equinix Inc vs Medtronic PLC — how do they compare? Equinix Inc trades at $1,018 (market cap $99.77B), while Medtronic PLC trades at $87.75 (market cap $112.24B). The key difference: Equinix Inc and Medtronic PLC are close in size by market cap, and Medtronic PLC pays the higher dividend (3.28%). Which is the better fit depends on your goals — on Pluang, investors hold Equinix Inc for 110 Days and Medtronic PLC for 63 Days on average.
| EQIX | MDT | |
|---|---|---|
Market Cap | $99.77B | $112.24B |
Volume | 480,425 | 105,663,236 |
Sector | Real Estate | Health |
52-Week High | $1.12K | $105.35 |
52-Week Low | $726.09 | $73.75 |
Typical Hold Time | 110 Days | 63 Days |
Enterprise Value | $120.90B | $131.58B |
Dividend Yield | 2.04% | 3.28% |
Signals from Pluang's Aura AI — not financial advice
Equinix (EQIX) trades at $1,031.77, down 1.49% on the day, amid a bullish technical setup with support at $1,025 and resistance at $1,042. The company reported revenue growth to $9.22B in 2025 and a net income margin of 15.63%, though it missed EPS estimates in two of the last three quarters. Recent news highlights strong AI-driven demand for data centers, with Equinix planning $5B-$7B in annual investments to expand capacity.
Outlook remains positive given analyst consensus of a $1,250 price target and 75% buy ratings, but risks include high valuation multiples (P/E 65.07) and rising debt-to-asset ratio (47.13% in 2025). The stock offers growth exposure to AI infrastructure trends, yet investors should weigh capex intensity against earnings sustainability.
Medtronic (MDT) trades at $85.51, down 1.81% on the day, with the stock showing bearish technical signals despite strong fundamental performance. The company has beaten earnings expectations for three consecutive quarters, maintains a healthy 13.93% net income margin, and offers a solid 3.2% dividend yield with 49 consecutive years of dividend growth. Recent positive developments include FDA clearances for new medical technologies and raised full-year guidance.
MDT presents a compelling value opportunity with analyst consensus pointing to 14% upside to the $97.80 price target. The stock's current valuation multiples (P/E 21.61, P/S 3.01) appear reasonable given the company's stable revenue growth and strong cash flow generation. Key risks include increasing debt levels and competitive pressures in the medical device sector, but the company's dividend aristocrat status and improving operational performance support a positive long-term outlook.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Equinix is a retail provider of data centers, enabling hundreds of enterprise tenants to house their servers and networking equipment in a collocated environment. Tenants can then connect with each other, through cloud service providers and telecom networks. Equinix operates 240 data centers in 66 markets worldwide and owns just less than half of them. The firm has roughly 10,000 customers, including 2,000 networks, that are dispersed over five verticals: Cloud and IT Services, Content Providers, Network and Mobile Services, Financial Services, and Enterprise. About 70% of Equinix's revenue comes from renting space to tenants and related services, and more than 15% comes from connecting customers with each other. Equinix operates as a real estate investment trust.
Read more on EQIX →One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →